NRX Pharmaceuticals, Inc.

NRXP Nasdaq SEC CIK 1719406
Follow NRX Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.2M +378.9% vs same quarter last year
Net income −$2.2M +63.1% vs same quarter last year
EPS, diluted −$0.05 +81.5% vs same quarter last year
Operating cash flow −$6.7M −132% vs same quarter last year
Revenue by quarter
$0
$0
$0
$242K
$983K
$1.1M
$1.1M
$1.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$100M−$75M−$50M−$25M$0$25MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1.2M−$28.6M
FY24$0−$25.1M
FY23$0−$30.2M
FY22-−$39.8M
FY21-−$93.1M
FY20-−$51.8M
FY19-$408.4K
FY18-$66.1K
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$10.6M
FY23−$21.7M
FY22−$39.8M
FY21−$37.7M
FY20−$2.3M
FY19-
FY18-
FY17-